ABVC ABVC BioPharma, Inc.
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.…
Industry Peers
BiotechnologyKey Statistics
About ABVC BioPharma (NASDAQ: ABVC)
›
ABVC BioPharma (NASDAQ: ABVC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 16 employees.
The shares were at 0.9100 USD on 13 November 2026, down 69.6% over 52 weeks. Its 52-week range is 0.7070 USD to 3.060 USD: the price is 70.3% below the high and 28.7% above the low.
Its market capitalisation is 24.55M USD.
ABVC BioPharma reports return on equity of -71.2% and an operating margin of 0.0%.
Its debt exceeds its cash by 2.44M USD, a debt-to-equity ratio of 0.31. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.